DexCom sets 10%+ annual organic revenue growth target through 2030; authorizes $1B share buyback

DEXCOM INC

Long-range target: organic revenue growth 10%+ every year through 2030.
2030 non-GAAP gross profit margin target of 67-69%; operating margin 29-30%.
2030 adjusted EBITDA margin target of 36-37%.
Board authorized $1.0B share repurchase program, expiring June 30, 2027.
Prior $250M remaining buyback program terminated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.